Ceritinib in advanced lung cancer: no evidence of additional benefits says IQWiG

1 October 2015 - Ceritinib (Zykadia) has been available since May 2015 for the treatment of adult patients with non small-cell ...

Read more →

Lomitapide mesylate in hypercholesterolaemia: IQWiG finds no hint of added clinical benefit (English version)

15 September 2015 - Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous ...

Read more →

German drug companies are criticised for not focusing on useful therapeutic areas

15 September 2015 - A 2011 German law designed to lower prices of new innovative drugs has not been as successful ...

Read more →

Lomitapide mesylate for hypercholesterolemia: no evidence of additional benefits

15 September 2015 - Lomitapide mesylate (trade name Lojuxta) has been approved since July 2013 for use by adults with homozygous ...

Read more →

IQWiG invites to its Autumn Symposium 2015

7 September 2015 - Benefit assessments of medical interventions are conducted to answer the question: What is the benefit and possible ...

Read more →

Secukinumab with plaque psoriasis: manufacturer dossier provides no evidence of an additional clinical enefit according to the IQWiG

1 September 2015 - Secukinumab (Cosentyx) was approved for use by adults with moderate to severe plaque psoriasis (psoriasis) in January ...

Read more →

Afatinib: added benefit in certain mutations confirmed by IQWiG

17 August 2015 - Afatinib dimaleate (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients ...

Read more →

Safinamide in Parkinson disease: no hint of added benefit says IQWiG

17 August 2015 - Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of ...

Read more →

Aclidinium bromide/formoterol in COPD: added benefit for certain patient groups

The fixed-dose combination aclidinium bromide/formoterol has been approved since November 2014 for long-term treatment of adults with chronic obstructive pulmonary ...

Read more →

Aflibercept in diabetic macular oedema: added benefit not proven

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular ...

Read more →

Fycompa (perampanel) to be resubmitted early to German Federal Joint Committee (G-BA) for additional benefit assessment

[:content [\9 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \T \h \e \space \G \e \r \m \a \n \space \F \e \d \e \r \a \l \space \J \o \i \n \t \space \C \o \m \m \i \t \t \e \e \space \( \G \- \B \A \) \, \space \t \h \e \space \d \e \c \i \s \i \o \n \- \m \a \k \i \n \g \space \b \o \d \y \space \o \f \space \t \h \e \space \s \e \l \f \- \g \o \v \e \r \n \i \n \g \space \h \e \a \l \t \h \c \a \r \e \space \s \y \s \t \e \m \space \i \n \  \G \e \r \m \a \n \y \, \space \r \e \c \e \n \t \l \y \space \c \o \n \f \i \r \m \e \d " ..."]]
Read more →

Added benefit of sucroferric oxyhydroxide is not proven

Sucroferric oxyhydroxide (trade name Velphoro) has been approved since August 2014 for adults with chronic kidney disease on haemodialysis or ...

Read more →

Dabrafenib: also no added benefit over vemurafenib

[:content [\3 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \D \a \b \r \a \f \e \n \i \b \space \( \T \a \f \i \n \l \a \r \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \s \i \n \c \e \space \A \u \g \u \s \t \space \2 \0 \1 \3 \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \a \d \v \a \n \c \e \d \space \m \e \l \a \n \o \m \a \. \space \I \n \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \, " ..."]]
Read more →

IQWiG rebuffs Gilead's Stribild (tenofovir disoproxil fumarate with emtricitabine and elvitegravir and cobicistat)

[:content [\I \Q \W \i \G \space \h \a \s \space \f \o \u \n \d \space \t \h \a \t \space \S \t \r \i \b \i \l \d \  \h \a \s \space \a \space \\ \" \s \m \a \l \l \e \r \\ \" \space \b \e \n \e \f \i \t \space \t \h \a \n \space \t \h \e \space \c \o \m \p \a \r \a \t \o \r \space \A \t \r \i \p \l \a \  \w \h \e \n \space \u \s \e \d \space \t \o \  \t \r \e \a \t \space \H \I \V \- \1 \space \i \n \f \e \c \t \i \o \n \space \i \n \space \t \r \e \a \t \m \e \n \t \- \n \a \Ã \¯ \v \e \space \a \d \u \l \t \s \space \o \r " ..."]]
Read more →

Nintedanib in lung cancer: added benefit depends on disease severity

Since November 2014 nintedanib (trade name: Vargatef) has been approved in combination with docetaxel for the treatment of adults with ...

Read more →